Review



atp6v0b  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech atp6v0b
    Effects of CANX and DHA on <t>ATP6V0B</t> and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.
    Atp6v0b, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/ATP6V1F+Antibody/pmc11332572-80-13-18
    Average 93 stars, based on 6 article reviews
    atp6v0b - by Bioz Stars, 2026-11
    93/100 stars

    Images

    1) Product Images from "Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX"

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX

    Journal: Oncology Letters

    doi: 10.3892/ol.2024.14607

    Effects of CANX and DHA on ATP6V0B and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.
    Figure Legend Snippet: Effects of CANX and DHA on ATP6V0B and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.

    Techniques Used: Expressing, Western Blot, Knock-Out, Over Expression, Negative Control, Small Interfering RNA

    Related Articles

    Expressing:

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4°C overnight.Subsequently, primary antibodies were added and incubated at 4°C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4˚C overnight.Subsequently, primary antibodies were added and incubated at 4˚C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903‑1‑Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671‑1‑AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β‑actin (1:2,000; cat. no. 20536‑1‑AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Western Blot:

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4°C overnight.Subsequently, primary antibodies were added and incubated at 4°C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4˚C overnight.Subsequently, primary antibodies were added and incubated at 4˚C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903‑1‑Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671‑1‑AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β‑actin (1:2,000; cat. no. 20536‑1‑AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Knock-Out:

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4°C overnight.Subsequently, primary antibodies were added and incubated at 4°C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4˚C overnight.Subsequently, primary antibodies were added and incubated at 4˚C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903‑1‑Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671‑1‑AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β‑actin (1:2,000; cat. no. 20536‑1‑AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Over Expression:

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4°C overnight.Subsequently, primary antibodies were added and incubated at 4°C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4˚C overnight.Subsequently, primary antibodies were added and incubated at 4˚C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903‑1‑Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671‑1‑AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β‑actin (1:2,000; cat. no. 20536‑1‑AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Negative Control:

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4°C overnight.Subsequently, primary antibodies were added and incubated at 4°C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4˚C overnight.Subsequently, primary antibodies were added and incubated at 4˚C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903‑1‑Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671‑1‑AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β‑actin (1:2,000; cat. no. 20536‑1‑AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Small Interfering RNA:

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4°C overnight.Subsequently, primary antibodies were added and incubated at 4°C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti-rabbit (1:5,000; cat. no. ZB-2301; OriGene Technologies, Inc.) or anti-mouse IgG (1:5,000; cat. no. ZB-2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.
    Article Snippet: Subsequently, primary antibodies were added and incubated at 4˚C overnight.Subsequently, primary antibodies were added and incubated at 4˚C overnight.. The primary antibodies used were CANX (1:5,000; cat. no. 66903‑1‑Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671‑1‑AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β‑actin (1:2,000; cat. no. 20536‑1‑AP; Proteintech Group, Inc.).. The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.The film was then washed three times with TBST (0.05% Tween 20), and then incubated with goat anti‑rabbit (1:5,000; cat. no. ZB‑2301; OriGene Technologies, Inc.) or anti‑mouse IgG (1:5,000; cat. no. ZB‑2305; OriGene Technologies, Inc.) labeled with horseradish peroxidase at room temperature for 1h.



    Similar Products

    atp6v0b gene  (Human Protein Atlas)
    90
    Human Protein Atlas atp6v0b gene
    Atp6v0b Gene, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/atp6v0b+gene/pm40598203-40-0-25
    Average 90 stars, based on 1 article reviews
    atp6v0b gene - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    atp6v0b rabbit antibody cat no: yn3416  (ImmunoWay Biotechnology Company)
    90
    ImmunoWay Biotechnology Company atp6v0b rabbit antibody cat no: yn3416
    <t>ATP6V0B</t> was upregulated in BCa. The GEPIA database was used to determine the mRNA level of ATP6V0B ( A ) and the overall survival of BCa patients ( B ). ( C ) The Kaplan-Meier (K-M) plotter was used to analyze the mRNA level of ATP6V0B and survival data. ( D ) RT-qPCR assays were performed to determine the mRNA level of ATP6V0B in BCa tumor tissues and adjacent normal tissues ( n = 30). ( E ) Western blotting assays were conducted to quantify the expression of ATP6V0B in four paired BCa tumor tissues and adjacent normal tissues. ( F ) Western blotting assays were performed to quantify the expression of ATP6V0B in a non-cancerous immortalized urothelial cell line SV-Huc-1 and four BCa cell lines, including J82, T24, UMUC3, and 5637; * p < 0.05 and ** p < 0.01
    Atp6v0b Rabbit Antibody Cat No: Yn3416, supplied by ImmunoWay Biotechnology Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/atp6v0b+rabbit+antibody+cat+no++yn3416/pmc12036214-70-10-17
    Average 90 stars, based on 1 article reviews
    atp6v0b rabbit antibody cat no: yn3416 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    rabbit anti-atp6v0b antibody  (ImmunoWay Biotechnology Company)
    90
    ImmunoWay Biotechnology Company rabbit anti-atp6v0b antibody
    <t>ATP6V0B</t> was upregulated in BCa. The GEPIA database was used to determine the mRNA level of ATP6V0B ( A ) and the overall survival of BCa patients ( B ). ( C ) The Kaplan-Meier (K-M) plotter was used to analyze the mRNA level of ATP6V0B and survival data. ( D ) RT-qPCR assays were performed to determine the mRNA level of ATP6V0B in BCa tumor tissues and adjacent normal tissues ( n = 30). ( E ) Western blotting assays were conducted to quantify the expression of ATP6V0B in four paired BCa tumor tissues and adjacent normal tissues. ( F ) Western blotting assays were performed to quantify the expression of ATP6V0B in a non-cancerous immortalized urothelial cell line SV-Huc-1 and four BCa cell lines, including J82, T24, UMUC3, and 5637; * p < 0.05 and ** p < 0.01
    Rabbit Anti Atp6v0b Antibody, supplied by ImmunoWay Biotechnology Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/atp6v0b+rabbit+antibody+cat+no++yn3416/pmc12036214-83-16-23
    Average 90 stars, based on 1 article reviews
    rabbit anti-atp6v0b antibody - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    atp6v0b  (Proteintech)
    93
    Proteintech atp6v0b
    Effects of CANX and DHA on <t>ATP6V0B</t> and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.
    Atp6v0b, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/ATP6V1F+Antibody/pmc11332572-80-13-18
    Average 93 stars, based on 1 article reviews
    atp6v0b - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    anti rabbit atp6v0b  (Novus Biologicals)
    92
    Novus Biologicals anti rabbit atp6v0b
    Effects of CANX and DHA on <t>ATP6V0B</t> and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.
    Anti Rabbit Atp6v0b, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/ATP6V0B+Antibody/pm38555350-351-0-8
    Average 92 stars, based on 1 article reviews
    anti rabbit atp6v0b - by Bioz Stars, 2026-11
    92/100 stars
    		  Buy from Supplier
    gene exp atp6v0b mm00504328 m1  (Thermo Fisher)
    88
    Thermo Fisher gene exp atp6v0b mm00504328 m1
    Effects of CANX and DHA on <t>ATP6V0B</t> and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.
    Gene Exp Atp6v0b Mm00504328 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atp6v0b/Gene+Exp%2E+Atp6v0b%2C+Mm00504328_m1/pmc06877313-399-44-13
    Average 88 stars, based on 1 article reviews
    gene exp atp6v0b mm00504328 m1 - by Bioz Stars, 2026-11
    88/100 stars
    		  Buy from Supplier

    Image Search Results


    ATP6V0B was upregulated in BCa. The GEPIA database was used to determine the mRNA level of ATP6V0B ( A ) and the overall survival of BCa patients ( B ). ( C ) The Kaplan-Meier (K-M) plotter was used to analyze the mRNA level of ATP6V0B and survival data. ( D ) RT-qPCR assays were performed to determine the mRNA level of ATP6V0B in BCa tumor tissues and adjacent normal tissues ( n = 30). ( E ) Western blotting assays were conducted to quantify the expression of ATP6V0B in four paired BCa tumor tissues and adjacent normal tissues. ( F ) Western blotting assays were performed to quantify the expression of ATP6V0B in a non-cancerous immortalized urothelial cell line SV-Huc-1 and four BCa cell lines, including J82, T24, UMUC3, and 5637; * p < 0.05 and ** p < 0.01

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B was upregulated in BCa. The GEPIA database was used to determine the mRNA level of ATP6V0B ( A ) and the overall survival of BCa patients ( B ). ( C ) The Kaplan-Meier (K-M) plotter was used to analyze the mRNA level of ATP6V0B and survival data. ( D ) RT-qPCR assays were performed to determine the mRNA level of ATP6V0B in BCa tumor tissues and adjacent normal tissues ( n = 30). ( E ) Western blotting assays were conducted to quantify the expression of ATP6V0B in four paired BCa tumor tissues and adjacent normal tissues. ( F ) Western blotting assays were performed to quantify the expression of ATP6V0B in a non-cancerous immortalized urothelial cell line SV-Huc-1 and four BCa cell lines, including J82, T24, UMUC3, and 5637; * p < 0.05 and ** p < 0.01

    Article Snippet: The primary antibodies used in this study are as follows: ATP6V0B rabbit antibody (Cat No: YN3416, 1:1000, Immunoway, China), β-Tubulin polyclonal antibody (Cat No: AC015, 1:5000, ABclonal, China), p85 monoclonal antibody (Cat No: A11177, 1:1000, ABclonal, China), p-p85 antibody (Cat No: ab191606, 1:1000, Abcam, USA), AKT antibody (Cat No: ab8805, 1:500, Abcam, USA), p-AKT (Ser473) antibody (Cat No: 80455-1-RR, 1:5000, Proteintech, China), E-cadherin antibody (Cat No: EPR16845-108, 1:1000, Abcam, USA), Vimentin (Cat No: A11952, 1:1000, ABclonal, China), and PAQR4 (Cat No: SAB2107001, 1:1000, Sigma-Aldrich, USA).

    Techniques: Quantitative RT-PCR, Western Blot, Expressing

    ATP6V0B increased the proliferation, migration, and invasion abilities of BCa cells in vitro. ( A ) The efficiency of the overexpression and knockdown of ATP6V0B plasmids was evaluated by RT-qPCR assays in BCa cells. ( B - D ) The CCK-8 assay was performed to measure the effects of the overexpression and knockdown of ATP6V0B on the proliferation of BCa cells. ( E ) The migration and invasion abilities of BCa cells were evaluated by overexpressing and knocking down ATP6V0B. ( F ) Western blotting analysis was performed to quantify the expression of ATP6V0B, E-cadherin, and Vimentin. ( G - I ) Quantification of the protein levels in ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B increased the proliferation, migration, and invasion abilities of BCa cells in vitro. ( A ) The efficiency of the overexpression and knockdown of ATP6V0B plasmids was evaluated by RT-qPCR assays in BCa cells. ( B - D ) The CCK-8 assay was performed to measure the effects of the overexpression and knockdown of ATP6V0B on the proliferation of BCa cells. ( E ) The migration and invasion abilities of BCa cells were evaluated by overexpressing and knocking down ATP6V0B. ( F ) Western blotting analysis was performed to quantify the expression of ATP6V0B, E-cadherin, and Vimentin. ( G - I ) Quantification of the protein levels in ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Article Snippet: The primary antibodies used in this study are as follows: ATP6V0B rabbit antibody (Cat No: YN3416, 1:1000, Immunoway, China), β-Tubulin polyclonal antibody (Cat No: AC015, 1:5000, ABclonal, China), p85 monoclonal antibody (Cat No: A11177, 1:1000, ABclonal, China), p-p85 antibody (Cat No: ab191606, 1:1000, Abcam, USA), AKT antibody (Cat No: ab8805, 1:500, Abcam, USA), p-AKT (Ser473) antibody (Cat No: 80455-1-RR, 1:5000, Proteintech, China), E-cadherin antibody (Cat No: EPR16845-108, 1:1000, Abcam, USA), Vimentin (Cat No: A11952, 1:1000, ABclonal, China), and PAQR4 (Cat No: SAB2107001, 1:1000, Sigma-Aldrich, USA).

    Techniques: Migration, In Vitro, Over Expression, Knockdown, Quantitative RT-PCR, CCK-8 Assay, Western Blot, Expressing

    Knocking down ATP6V0B suppressed tumor growth in vivo. ( A ) The representative photographs of tumors were taken from nude mice 21 days after inoculation ( n = 6). ( B and C ) The volume and weight of the tumors were measured after the tumors were isolated. ( D ) RT-qPCR analysis was performed to evaluate the mRNA levels of ATP6V0B in tumor tissues. ( E ) The expression of ATP6V0B in tumor tissues was confirmed by IHC; **** p < 0.0001

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: Knocking down ATP6V0B suppressed tumor growth in vivo. ( A ) The representative photographs of tumors were taken from nude mice 21 days after inoculation ( n = 6). ( B and C ) The volume and weight of the tumors were measured after the tumors were isolated. ( D ) RT-qPCR analysis was performed to evaluate the mRNA levels of ATP6V0B in tumor tissues. ( E ) The expression of ATP6V0B in tumor tissues was confirmed by IHC; **** p < 0.0001

    Article Snippet: The primary antibodies used in this study are as follows: ATP6V0B rabbit antibody (Cat No: YN3416, 1:1000, Immunoway, China), β-Tubulin polyclonal antibody (Cat No: AC015, 1:5000, ABclonal, China), p85 monoclonal antibody (Cat No: A11177, 1:1000, ABclonal, China), p-p85 antibody (Cat No: ab191606, 1:1000, Abcam, USA), AKT antibody (Cat No: ab8805, 1:500, Abcam, USA), p-AKT (Ser473) antibody (Cat No: 80455-1-RR, 1:5000, Proteintech, China), E-cadherin antibody (Cat No: EPR16845-108, 1:1000, Abcam, USA), Vimentin (Cat No: A11952, 1:1000, ABclonal, China), and PAQR4 (Cat No: SAB2107001, 1:1000, Sigma-Aldrich, USA).

    Techniques: In Vivo, Isolation, Quantitative RT-PCR, Expressing, Paraffin-embedded Immunohistochemistry

    ATP6V0B activated PI3K/AKT signaling in BCa cells. ( A ) GSEA results showed that the PI3K/AKT signaling pathway was hyperactivated in BCa cells. ( B ) Western blotting assays were performed to determine the indicated protein levels of PI3K/AKT signaling. ( C ) Quantification of the protein expression levels in ( B ). ( D ) The BCa cells were transfected with the pcDNA3 empty vector and the ATP6V0B-overexpressing vector for 24 h, after which the cells were treated with LY294002 (10 µM) for 24 h. Western blotting assays were performed to determine the level of p85, p-p85, AKT, and p-AKT proteins. ( E ) Quantification of the protein levels in ( D ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B activated PI3K/AKT signaling in BCa cells. ( A ) GSEA results showed that the PI3K/AKT signaling pathway was hyperactivated in BCa cells. ( B ) Western blotting assays were performed to determine the indicated protein levels of PI3K/AKT signaling. ( C ) Quantification of the protein expression levels in ( B ). ( D ) The BCa cells were transfected with the pcDNA3 empty vector and the ATP6V0B-overexpressing vector for 24 h, after which the cells were treated with LY294002 (10 µM) for 24 h. Western blotting assays were performed to determine the level of p85, p-p85, AKT, and p-AKT proteins. ( E ) Quantification of the protein levels in ( D ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Article Snippet: The primary antibodies used in this study are as follows: ATP6V0B rabbit antibody (Cat No: YN3416, 1:1000, Immunoway, China), β-Tubulin polyclonal antibody (Cat No: AC015, 1:5000, ABclonal, China), p85 monoclonal antibody (Cat No: A11177, 1:1000, ABclonal, China), p-p85 antibody (Cat No: ab191606, 1:1000, Abcam, USA), AKT antibody (Cat No: ab8805, 1:500, Abcam, USA), p-AKT (Ser473) antibody (Cat No: 80455-1-RR, 1:5000, Proteintech, China), E-cadherin antibody (Cat No: EPR16845-108, 1:1000, Abcam, USA), Vimentin (Cat No: A11952, 1:1000, ABclonal, China), and PAQR4 (Cat No: SAB2107001, 1:1000, Sigma-Aldrich, USA).

    Techniques: Western Blot, Expressing, Transfection, Plasmid Preparation

    ATP6V0B upregulated the expression of PAQR4 in BCa. ( A ) The Venn diagram shows that there are 54 genes that are positively correlated with ATP6V0B and upregulated in BCa, and among these 54 genes, 15 genes have significantly different survival curves. ( B - D ) The GEPIA database was used to analyze the correlation between ATP6V0B and PAQR4 ( B ), the level of PAQR4 mRNA ( C ), and overall survival, as determined by the level of PAQR4 mRNA ( D ). ( E ) The K-M plotter was used to validate the overall survival of PAQR4. ( F ) RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA in BCa tumor tissues and adjacent normal tissues ( n = 30). ( G ) The correlation between ATP6V0B and PAQR4 was analyzed based on the level of mRNA of ATP6V0B and PAQR4. ( H ) BCa cells were transfected with the indicated plasmids, and RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA 36 h after transfection. ( I ) Western blotting analysis was performed to measure the expression of PAQR4 48 h after transfection; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B upregulated the expression of PAQR4 in BCa. ( A ) The Venn diagram shows that there are 54 genes that are positively correlated with ATP6V0B and upregulated in BCa, and among these 54 genes, 15 genes have significantly different survival curves. ( B - D ) The GEPIA database was used to analyze the correlation between ATP6V0B and PAQR4 ( B ), the level of PAQR4 mRNA ( C ), and overall survival, as determined by the level of PAQR4 mRNA ( D ). ( E ) The K-M plotter was used to validate the overall survival of PAQR4. ( F ) RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA in BCa tumor tissues and adjacent normal tissues ( n = 30). ( G ) The correlation between ATP6V0B and PAQR4 was analyzed based on the level of mRNA of ATP6V0B and PAQR4. ( H ) BCa cells were transfected with the indicated plasmids, and RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA 36 h after transfection. ( I ) Western blotting analysis was performed to measure the expression of PAQR4 48 h after transfection; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Article Snippet: The primary antibodies used in this study are as follows: ATP6V0B rabbit antibody (Cat No: YN3416, 1:1000, Immunoway, China), β-Tubulin polyclonal antibody (Cat No: AC015, 1:5000, ABclonal, China), p85 monoclonal antibody (Cat No: A11177, 1:1000, ABclonal, China), p-p85 antibody (Cat No: ab191606, 1:1000, Abcam, USA), AKT antibody (Cat No: ab8805, 1:500, Abcam, USA), p-AKT (Ser473) antibody (Cat No: 80455-1-RR, 1:5000, Proteintech, China), E-cadherin antibody (Cat No: EPR16845-108, 1:1000, Abcam, USA), Vimentin (Cat No: A11952, 1:1000, ABclonal, China), and PAQR4 (Cat No: SAB2107001, 1:1000, Sigma-Aldrich, USA).

    Techniques: Expressing, Quantitative RT-PCR, Transfection, Western Blot

    ATP6V0B increased the malignant behavior of BCa cells and activation of PI3K/AKT signaling by upregulating PAQR4. BCa cells were transfected with pcDNA3 + pSilencer2.1, ATP6V0B + pSilencer2.1, and ATP6V0B + pshR-PAQR4, after which the abilities of the cells to proliferate ( A ), migrate, and invade ( B ) were evaluated. ( C ) Western blotting assays were conducted to determine the levels of the proteins associated with the PI3K/AKT signaling pathway affected by the overexpression of PAQR4. ( D ) Quantification of the protein levels in ( C ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B increased the malignant behavior of BCa cells and activation of PI3K/AKT signaling by upregulating PAQR4. BCa cells were transfected with pcDNA3 + pSilencer2.1, ATP6V0B + pSilencer2.1, and ATP6V0B + pshR-PAQR4, after which the abilities of the cells to proliferate ( A ), migrate, and invade ( B ) were evaluated. ( C ) Western blotting assays were conducted to determine the levels of the proteins associated with the PI3K/AKT signaling pathway affected by the overexpression of PAQR4. ( D ) Quantification of the protein levels in ( C ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Article Snippet: The primary antibodies used in this study are as follows: ATP6V0B rabbit antibody (Cat No: YN3416, 1:1000, Immunoway, China), β-Tubulin polyclonal antibody (Cat No: AC015, 1:5000, ABclonal, China), p85 monoclonal antibody (Cat No: A11177, 1:1000, ABclonal, China), p-p85 antibody (Cat No: ab191606, 1:1000, Abcam, USA), AKT antibody (Cat No: ab8805, 1:500, Abcam, USA), p-AKT (Ser473) antibody (Cat No: 80455-1-RR, 1:5000, Proteintech, China), E-cadherin antibody (Cat No: EPR16845-108, 1:1000, Abcam, USA), Vimentin (Cat No: A11952, 1:1000, ABclonal, China), and PAQR4 (Cat No: SAB2107001, 1:1000, Sigma-Aldrich, USA).

    Techniques: Activation Assay, Transfection, Western Blot, Over Expression

    ATP6V0B was upregulated in BCa. The GEPIA database was used to determine the mRNA level of ATP6V0B ( A ) and the overall survival of BCa patients ( B ). ( C ) The Kaplan-Meier (K-M) plotter was used to analyze the mRNA level of ATP6V0B and survival data. ( D ) RT-qPCR assays were performed to determine the mRNA level of ATP6V0B in BCa tumor tissues and adjacent normal tissues ( n = 30). ( E ) Western blotting assays were conducted to quantify the expression of ATP6V0B in four paired BCa tumor tissues and adjacent normal tissues. ( F ) Western blotting assays were performed to quantify the expression of ATP6V0B in a non-cancerous immortalized urothelial cell line SV-Huc-1 and four BCa cell lines, including J82, T24, UMUC3, and 5637; * p < 0.05 and ** p < 0.01

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B was upregulated in BCa. The GEPIA database was used to determine the mRNA level of ATP6V0B ( A ) and the overall survival of BCa patients ( B ). ( C ) The Kaplan-Meier (K-M) plotter was used to analyze the mRNA level of ATP6V0B and survival data. ( D ) RT-qPCR assays were performed to determine the mRNA level of ATP6V0B in BCa tumor tissues and adjacent normal tissues ( n = 30). ( E ) Western blotting assays were conducted to quantify the expression of ATP6V0B in four paired BCa tumor tissues and adjacent normal tissues. ( F ) Western blotting assays were performed to quantify the expression of ATP6V0B in a non-cancerous immortalized urothelial cell line SV-Huc-1 and four BCa cell lines, including J82, T24, UMUC3, and 5637; * p < 0.05 and ** p < 0.01

    Article Snippet: Subsequently, the sections were blocked with a 5% BSA and incubated at 4 °C overnight with rabbit anti-ATP6V0B antibody (Cat No: YN3416, 1:100, Immunoway, China) and Ki67Ki67 antibody (Cat No: ab15580, 1:500, Abcam, USA).

    Techniques: Quantitative RT-PCR, Western Blot, Expressing

    ATP6V0B increased the proliferation, migration, and invasion abilities of BCa cells in vitro. ( A ) The efficiency of the overexpression and knockdown of ATP6V0B plasmids was evaluated by RT-qPCR assays in BCa cells. ( B - D ) The CCK-8 assay was performed to measure the effects of the overexpression and knockdown of ATP6V0B on the proliferation of BCa cells. ( E ) The migration and invasion abilities of BCa cells were evaluated by overexpressing and knocking down ATP6V0B. ( F ) Western blotting analysis was performed to quantify the expression of ATP6V0B, E-cadherin, and Vimentin. ( G - I ) Quantification of the protein levels in ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B increased the proliferation, migration, and invasion abilities of BCa cells in vitro. ( A ) The efficiency of the overexpression and knockdown of ATP6V0B plasmids was evaluated by RT-qPCR assays in BCa cells. ( B - D ) The CCK-8 assay was performed to measure the effects of the overexpression and knockdown of ATP6V0B on the proliferation of BCa cells. ( E ) The migration and invasion abilities of BCa cells were evaluated by overexpressing and knocking down ATP6V0B. ( F ) Western blotting analysis was performed to quantify the expression of ATP6V0B, E-cadherin, and Vimentin. ( G - I ) Quantification of the protein levels in ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Article Snippet: Subsequently, the sections were blocked with a 5% BSA and incubated at 4 °C overnight with rabbit anti-ATP6V0B antibody (Cat No: YN3416, 1:100, Immunoway, China) and Ki67Ki67 antibody (Cat No: ab15580, 1:500, Abcam, USA).

    Techniques: Migration, In Vitro, Over Expression, Knockdown, Quantitative RT-PCR, CCK-8 Assay, Western Blot, Expressing

    Knocking down ATP6V0B suppressed tumor growth in vivo. ( A ) The representative photographs of tumors were taken from nude mice 21 days after inoculation ( n = 6). ( B and C ) The volume and weight of the tumors were measured after the tumors were isolated. ( D ) RT-qPCR analysis was performed to evaluate the mRNA levels of ATP6V0B in tumor tissues. ( E ) The expression of ATP6V0B in tumor tissues was confirmed by IHC; **** p < 0.0001

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: Knocking down ATP6V0B suppressed tumor growth in vivo. ( A ) The representative photographs of tumors were taken from nude mice 21 days after inoculation ( n = 6). ( B and C ) The volume and weight of the tumors were measured after the tumors were isolated. ( D ) RT-qPCR analysis was performed to evaluate the mRNA levels of ATP6V0B in tumor tissues. ( E ) The expression of ATP6V0B in tumor tissues was confirmed by IHC; **** p < 0.0001

    Article Snippet: Subsequently, the sections were blocked with a 5% BSA and incubated at 4 °C overnight with rabbit anti-ATP6V0B antibody (Cat No: YN3416, 1:100, Immunoway, China) and Ki67Ki67 antibody (Cat No: ab15580, 1:500, Abcam, USA).

    Techniques: In Vivo, Isolation, Quantitative RT-PCR, Expressing, Paraffin-embedded Immunohistochemistry

    ATP6V0B activated PI3K/AKT signaling in BCa cells. ( A ) GSEA results showed that the PI3K/AKT signaling pathway was hyperactivated in BCa cells. ( B ) Western blotting assays were performed to determine the indicated protein levels of PI3K/AKT signaling. ( C ) Quantification of the protein expression levels in ( B ). ( D ) The BCa cells were transfected with the pcDNA3 empty vector and the ATP6V0B-overexpressing vector for 24 h, after which the cells were treated with LY294002 (10 µM) for 24 h. Western blotting assays were performed to determine the level of p85, p-p85, AKT, and p-AKT proteins. ( E ) Quantification of the protein levels in ( D ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B activated PI3K/AKT signaling in BCa cells. ( A ) GSEA results showed that the PI3K/AKT signaling pathway was hyperactivated in BCa cells. ( B ) Western blotting assays were performed to determine the indicated protein levels of PI3K/AKT signaling. ( C ) Quantification of the protein expression levels in ( B ). ( D ) The BCa cells were transfected with the pcDNA3 empty vector and the ATP6V0B-overexpressing vector for 24 h, after which the cells were treated with LY294002 (10 µM) for 24 h. Western blotting assays were performed to determine the level of p85, p-p85, AKT, and p-AKT proteins. ( E ) Quantification of the protein levels in ( D ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Article Snippet: Subsequently, the sections were blocked with a 5% BSA and incubated at 4 °C overnight with rabbit anti-ATP6V0B antibody (Cat No: YN3416, 1:100, Immunoway, China) and Ki67Ki67 antibody (Cat No: ab15580, 1:500, Abcam, USA).

    Techniques: Western Blot, Expressing, Transfection, Plasmid Preparation

    ATP6V0B upregulated the expression of PAQR4 in BCa. ( A ) The Venn diagram shows that there are 54 genes that are positively correlated with ATP6V0B and upregulated in BCa, and among these 54 genes, 15 genes have significantly different survival curves. ( B - D ) The GEPIA database was used to analyze the correlation between ATP6V0B and PAQR4 ( B ), the level of PAQR4 mRNA ( C ), and overall survival, as determined by the level of PAQR4 mRNA ( D ). ( E ) The K-M plotter was used to validate the overall survival of PAQR4. ( F ) RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA in BCa tumor tissues and adjacent normal tissues ( n = 30). ( G ) The correlation between ATP6V0B and PAQR4 was analyzed based on the level of mRNA of ATP6V0B and PAQR4. ( H ) BCa cells were transfected with the indicated plasmids, and RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA 36 h after transfection. ( I ) Western blotting analysis was performed to measure the expression of PAQR4 48 h after transfection; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B upregulated the expression of PAQR4 in BCa. ( A ) The Venn diagram shows that there are 54 genes that are positively correlated with ATP6V0B and upregulated in BCa, and among these 54 genes, 15 genes have significantly different survival curves. ( B - D ) The GEPIA database was used to analyze the correlation between ATP6V0B and PAQR4 ( B ), the level of PAQR4 mRNA ( C ), and overall survival, as determined by the level of PAQR4 mRNA ( D ). ( E ) The K-M plotter was used to validate the overall survival of PAQR4. ( F ) RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA in BCa tumor tissues and adjacent normal tissues ( n = 30). ( G ) The correlation between ATP6V0B and PAQR4 was analyzed based on the level of mRNA of ATP6V0B and PAQR4. ( H ) BCa cells were transfected with the indicated plasmids, and RT-qPCR analysis was performed to evaluate the level of PAQR4 mRNA 36 h after transfection. ( I ) Western blotting analysis was performed to measure the expression of PAQR4 48 h after transfection; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Article Snippet: Subsequently, the sections were blocked with a 5% BSA and incubated at 4 °C overnight with rabbit anti-ATP6V0B antibody (Cat No: YN3416, 1:100, Immunoway, China) and Ki67Ki67 antibody (Cat No: ab15580, 1:500, Abcam, USA).

    Techniques: Expressing, Quantitative RT-PCR, Transfection, Western Blot

    ATP6V0B increased the malignant behavior of BCa cells and activation of PI3K/AKT signaling by upregulating PAQR4. BCa cells were transfected with pcDNA3 + pSilencer2.1, ATP6V0B + pSilencer2.1, and ATP6V0B + pshR-PAQR4, after which the abilities of the cells to proliferate ( A ), migrate, and invade ( B ) were evaluated. ( C ) Western blotting assays were conducted to determine the levels of the proteins associated with the PI3K/AKT signaling pathway affected by the overexpression of PAQR4. ( D ) Quantification of the protein levels in ( C ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Journal: BMC Cancer

    Article Title: ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling

    doi: 10.1186/s12885-025-14183-z

    Figure Lengend Snippet: ATP6V0B increased the malignant behavior of BCa cells and activation of PI3K/AKT signaling by upregulating PAQR4. BCa cells were transfected with pcDNA3 + pSilencer2.1, ATP6V0B + pSilencer2.1, and ATP6V0B + pshR-PAQR4, after which the abilities of the cells to proliferate ( A ), migrate, and invade ( B ) were evaluated. ( C ) Western blotting assays were conducted to determine the levels of the proteins associated with the PI3K/AKT signaling pathway affected by the overexpression of PAQR4. ( D ) Quantification of the protein levels in ( C ); * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, no significant difference

    Article Snippet: Subsequently, the sections were blocked with a 5% BSA and incubated at 4 °C overnight with rabbit anti-ATP6V0B antibody (Cat No: YN3416, 1:100, Immunoway, China) and Ki67Ki67 antibody (Cat No: ab15580, 1:500, Abcam, USA).

    Techniques: Activation Assay, Transfection, Western Blot, Over Expression

    Effects of CANX and DHA on ATP6V0B and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.

    Journal: Oncology Letters

    Article Title: Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX

    doi: 10.3892/ol.2024.14607

    Figure Lengend Snippet: Effects of CANX and DHA on ATP6V0B and ATP6V1F expression. (A) Expression of (B) CANX, (C) ATP6V0B and (D) ATP6V1F in HuH-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. (E) Expression of (F) CANX, (G) ATP6V0B and (H) ATP6V1F in Li-7 cells, detected by western blotting after CANX knockout, DHA or CANX overexpression. **P<0.01; ***P<0.001. CANX, calnexin; DHA, dihydroartemisinin; NC, negative control; siRNA, small interfering RNA.

    Article Snippet: The primary antibodies used were CANX (1:5,000; cat. no. 66903-1-Ig; Proteintech Group, Inc.), ATP6V0B (1:1,000; cat. no. 27671-1-AP; Proteintech Group, Inc.) and ATP6V1F (1:1,000; ab190789; Abcam), β-actin (1:2,000; cat. no. 20536-1-AP; Proteintech Group, Inc.).

    Techniques: Expressing, Western Blot, Knock-Out, Over Expression, Negative Control, Small Interfering RNA